MEB Annual report 2014

The Medicines Evaluation Board (MEB) assesses and monitors the efficacy, risks and quality of medicinal products for human and veterinary use. The MEB also evaluates the safety of novel foods for human consumption. In this annual report, we look back at the developments in 2014.

Transition

For the MEB, 2014 was a year marked by transition. At the start of the year, after 10 years of service the MEB bid farewell with great appreciation to Executive Director Aginus Kalis. Deputy Director Stan van Belkum filled in temporarily until Hugo Hurts took up the post as the new Executive Director in June 2014. The organisation implemented several substantial measures in 2014 to ensure a positive financial result at the end of the year. The transition to a patient-oriented and more communicative organisation was strengthened in 2014. The new Executive Director Hugo Hurts and the Chair Bert Leufkens recall the steps taken by the MEB in the past year.